Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib
Hidalgo-Ríos, Samuel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Carrillo García, Jaime (Hospital Universitario General de Villalba. Servicio de Oncología Médica)
Moura, David S. (Hospital Universitario General de Villalba. Servicio de Oncología Médica)
Stacchiotti, Silvia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia))
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau)
Redondo, Andrés (Hospital Universitario La Paz. Servicio de Oncología Médica. Instituto de Investigación en Salud (IdiPAZ))
Italiano, Antoine (Institut Bergonié. Department of Oncology)
Gutiérrez, Antonio (Hospital Universitari Son Espases (Palma de Mallorca, Balears))
Grignani, Giovanni (Candiolo Cancer Institute. FPO - IRCCS)
Hindi, Nadia (Hospital Universitario Fundación Jiménez Díaz. Servicio de Oncología Médica)
López-Guerrero, J.A (Laboratory of Molecular Biology. Fundación Instituto Valenciano de Oncología)
Garcia del Muro, Xavier (Institut d'Investigació Biomèdica de Bellvitge)
Martínez-Trufero, Javier (Hospital Universitario Miguel Servet. Servicio de Oncología Médica)
Palmerini, Emanuela (IRCCS Istituto Ortopedico Rizzoli (Bologna))
Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau)
Bernabeu, Daniel (Hospital Universitario La Paz. Sección de Radiología musculoesquelética)
Le Cesne, Axel (Gustave Roussy Cancer Campus. Department of Medical Oncology)
Casali, Paolo Giovanni (Fondazione IRCCS Istituto Nazionale dei Tumori. Adult Mesenchymal and Rare Tumor Unit. Department of Cancer Medicine)
Blay, Jean-Yves (Department of Medical Oncology. Centre Léon Bérard. Université Claude Bernard Lyon)
Cruz-Jurado, Josefina (Hospital Universitario de Canarias. Servicio de Oncología Médica)
Martín-Broto, Javier (Hospital Universitario Fundación Jiménez Díaz. Servicio de Oncología Médica)

Data:	2022
Resum:	Pazopanib was assessed prospectively in the GEIS-32 phase II study (NCT02066285) on advanced solitary fibrous tumour (SFT), resulting in a longer progression-free survival (PFS) and overall survival (OS) compared with historical controls treated with chemotherapy. A retrospective analysis of peripheral inflammatory indexes in patients enrolled into GEIS-32 was performed to evaluate their prognostic and predictive value. Patients received pazopanib 800 mg/day as the first antiangiogenic line. The impacts of baseline neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and red cell distribution width (RDW) on PFS, OS, and Choi response were evaluated by univariate and multivariate analysis. Metastasis-free interval (MFI), mitotic count, and ECOG were also included as potential prognostic factors. Sixty-seven SFT patients, enrolled in this study, showed a median age of 63 years and a female/male distribution of 57/43. The median follow-up from treatment initiation was 16. 8 months. High baseline NLR, PLR, and standardised RDW were significantly associated with worse PFS and OS. NLR, RDW, MFI, and mitotic count were independent variables for PFS, while RDW and ECOG were independent for OS. Further, NLR and mitotic count were independent factors for Choi response. High baseline NLR and RDW values were independent prognostic biomarkers for worse outcome in advanced SFT patients treated with pazopanib.
Ajuts:	Instituto de Salud Carlos III CD20/00155 Instituto de Salud Carlos III PI18/01728 European Commission. Horizon 2020 825806
Nota:	Altres ajuts: Fondo Europeo de Desarrollo Regional (FEDER).
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Solitary fibrous tumour ; Pazopanib ; Inflammation ; Neutrophil/lymphocyte ratio ; NLR ; Platelet/lymphocyte ; PLR ; Red cell distribution width ; RDW
Publicat a:	Cancers, Vol. 14 Núm. 17 (september 2022) , p. 4186, ISSN 2072-6694

DOI: 10.3390/cancers14174186
PMID: 36077723

12 p, 682.4 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats